{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-001226","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.078806+00:00","generated_at":"2026-05-28T03:46:26.067121+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn reports $243.8M cash runway into 2027; pipeline milestones for FHD-909, CBP/EP300 degraders","bullets":["Preliminary cash, equivalents and marketable securities of $243.8M as of Dec 31, 2024; runway into 2027.","Phase 1 trial of oral SMARCA2 inhibitor FHD-909 for SMARCA4-mutated cancers advancing; NSCLC primary target.","Preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors to be presented at AACR April 2025.","Selective ARID1B degradation achieved; program update expected in 2025. ARID1B implicated in up to 5% of solid tumors.","Selective CBP and EP300 degrader programs advancing with preclinical data showing anti-tumor activity and tolerability."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-001226","json":"https://secwatch.observer/filing/0001628280-25-001226.json","markdown":"https://secwatch.observer/filing/0001628280-25-001226.md","text":"https://secwatch.observer/filing/0001628280-25-001226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025001226/0001628280-25-001226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025001226/fhtx-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:46:26.067121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}